Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar (DOLCI)

Hamad Medical Corporation (HMC)

Status: Completed

Conditions: COVID; Pneumonia; Coronavirus

Treatments: Drug: Darunavir/Cobicistat; Drug: Lopinavir/Ritonavir

Study type: Observational

Funder types: Industry

Identifiers

NCT04425382

MRC-05-069

Details and patient eligibility

About

Coronavirus Disease 2019 (COVID-19) is a disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. It was first isolated in Wuhan, China in December 2019 and then rapidly spread to the rest of the world posing a severe threat to global health.

Many therapeutics have been investigated for the treatment of this disease with inconclusive outcomes. Protease inhibitors are one of the proposed agents, but their use is limited to their significant drug interactions and side effects.

The aim of this study is to compare the efficacy and safety outcomes of Darunavir/Cobicistat versus Lopinavir /Ritonavir in the treatment of patients with COVID-19 pneumonia in Qatar.

Enrollment: 400 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients ≥18 years of age
• Laboratory confirmed 2019-nCoV infection as determined by the PCR of the nasopharyngeal/oropharyngeal swab.
• Radiologically confirmed pneumonia (Based on the chest x-ray or CT scan imaging).
• Have received either Darunavir/Cobicistat or Lopinavir/Ritonavir as part of the treatment regimen for COVID-19 pneumonia

Exclusion criteria

• No exclusion criteria will be applied

Trial design

400 participants in 2 patient groups

Darunavir/Cobicistat

Description:

Patients received Darunavir/Cobicistat (Rezolsta®) as part of the treatment regimen for COVID-19 pneumonia

Treatment:

Drug: Darunavir/Cobicistat

Lopinavir/Ritonavir

Description:

Patient received Lopinavir/Ritonavir (Kaletra®) as part of the treatment regimen for COVID-19 pneumonia

Treatment:

Drug: Lopinavir/Ritonavir